Claims for Patent: 6,586,238

Summary for Patent: 6,586,238

Title:	Enzymatic nucleic acids containing 5\'-and or 3\'-cap structures
Abstract:	An enzymatic nucleic acid molecule comprising a 5\'- and/or a 3\'-cap structure, wherein said structure is not a 5\'-5\'-linked inverted nucleotide or a 3\'-3\'-linked inverted nucleotide.
Inventor(s):	Matulic-Adamic; Jasenka (Boulder, CO), Beigelman; Leonid (Longmont, CO), Karpeisky; Alexander (Boulder, CO), Jarvis; Thale (Boulder, CO), Usman; Nassim (Boulder, CO), DiRenzo; Anthony (Boulder, CO), Wincott; Francine (Longmont, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	09/419,125
Patent Claims:	1. A nucleic acid molecule comprising a 5'-cap structure, a 3'-cap structure, or both a 5'- and a 3'-cap structure, wherein said 5'-cap structure is selected from the group consisting of 4',5'-methylene nucleotide; 1-(.beta.-D-erythrofuranosyl) nucleotide; 1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate; 12-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,5-dihydroxypentyl nucleotide; and 5'-mercapto moieties, and wherein said 3'-cap structure is selected from the group consisting of 1,5-anhydrohexitol nucleotide; L-nucleotide; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,5-dihydroxypentyl nucleotide; 3'-2'-inverted nucleotide moiety; 3'-2'-inverted abasic moiety; and 1,4-butanediol. 2. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is in an enzymatic nucleic acid molecule. 3. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is in an antisense nucleic acid molecule. 4. The nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule is in a hairpin, hepatitis delta virus, group I intron, VS RNA or RNase P RNA motif. 5. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises said 5'-cap structure. 6. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises said 3'-cap structure. 7. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises said 5'-cap structure and said 3'-cap structure. 8. The nucleic acid molecule of claim 1, wherein said 5'- and 3'-cap structures are different. 9. The nucleic acid molecule of claim 1, wherein said 5'- and 3'-cap structures are same. 10. The nucleic acid of claim 1, wherein said 3'-cap structure is a 3'-2' linked inverted nucleotide. 11. The nucleic acid of claim 1, wherein said 3'-cap structure is a 3'-2' linked inverted abasic moiety. 12. The nucleic acid of claim 1, wherein said 5'-cap structure is a 1,3-diamino-2propyl phosphate group. 13. The nucleic acid of claim 1, wherein said 5'-cap structure is a L-nucleotide. 14. The nucleic acid of claim 1, wherein said 5'-cap structure is a threo-pentafuranosyl group. 15. The nucleic acid of claim 1, wherein said 5'-cap structure is a 3,5-dihydroxypentyl nucleotide. 16. The nucleic acid of claim 1, wherein said 5'-cap structure is a 1-(.beta.-D-erythrofuranosyl) nucleotide. 17. The nucleic acid of claim 1, wherein said 3'-cap structure is a L-nucleotide. 18. The nucleic acid of claim 1, wherein said 3'-cap structure is a 3,5-dihydroxypentyl nucleotide. 19. An isolated mammalian cell comprising the nucleic acid molecule of claim 1. 20. The mammalian cell of claim 19, wherein said mammalian cell is a human cell.

Details for Patent 6,586,238

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-04-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-04-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-04-16